Rola melatoniny w chorobach przewodu pokarmowego

• Authors: Maria Wiśniewska-Jarosińska , Jan Chojnacki

Title variants

EN

Role of melatonin in the gastrointestinal tract disease

• Languages of publication: PL

Abstracts

PL

Melatonina (MEL) pełni rolę bardzo waŜnego enterohormonu w przewodzie pokarmowym. Pomimo, Ŝe od momentu jej wyizolowania z szyszynki przez Aarona Lernera w 1958 roku minęło ponad 50 lat wciąŜ poznajemy nowe aspekty jej działania. Wielu badaczy potwierdziło wysokie stęŜenia MEL w tkankach przewodu pokarmowego, wielokrotnie przewyŜszające wartości stęŜeń we krwi obwodowej. W szeregu schorzeń układu trawiennego opisano zmiany sekrecji i metabolizmu MEL. Są one często następstwem tych chorób, ale z drugiej strony w istotny sposób mogą takŜe wpływać na ich obraz kliniczny. W miarę poznawania funkcji fizjologicznych MEL oraz roli zaburzeń jej homeostazy w patogenezie wielu schorzeń poszerzamy równieŜ moŜliwości jej terapeutycznego wykorzystania w leczeniu wspomagającym wielu chorób czynnościowych i organicznych przewodu pokarmowego. W pracy przedstawiono zbiorczo informacje dotyczące roli MEL w wybranych chorobach przewodu pokarmowego.

EN

Melatonin (MEL) plays a role of an important enterehormone in the gastrointestinal tract. Although more than fifty years have already passed since the moment of its isolation from the pineal gland by Aaron Lerner in 1958, we still reveal new aspects of its action. A number of researchers confirmed the high MEL concentration in the gut tissues, several times surpassing its concentration in peripheral blood. The changes of MEL secretion and metabolism have been described in many gastrointestinal disorders. They can be the consequence of the diseases, but they also do not remain without an effect on the clinical picture of these disorders. With increasing knowledge about physiological function of melatonin and the role of its disturbed homeostasis in the pathogenesis of many gastrointestinal diseases, the indications for its therapeutic use in the supportive treatment of many functional and organic gastrointestinal diseases are being widened. In this paper the authors present a comprehensive review on the role of MEL in the selected diseases of the gut.

Keywords

EN

enterochromaffin cells; gastrointestinal tract.; komórki enterochromafinowe; melatonin; melatonina; melatoninergic receptors; przewód pokarmowy; receptorymelatoninowe

Discipline

• MEDICINE: MEDICINE

• Publisher: Łódzkie Towarzystwo Naukowe
• Journal: Folia Medica Lodziensia
• Year: 2010
• Volume: 37
• Issue: 1
• Pages: 89-109

Contributors

author

Maria Wiśniewska-Jarosińska

• Klinika Gastroenterologii i Chorób Wewnętrznych, Katedra Medycyny Wewnętrznej, Uniwersytet Medyczny w Łodzi, Centralny Szpital Weteranów im. WAM

author

Jan Chojnacki

• Klinika Gastroenterologii i Chorób Wewnętrznych, Katedra Medycyny Wewnętrznej, Uniwersytet Medyczny w Łodzi, Centralny Szpital Weteranów im. WAM

References

• Lerner AB, Case JD, Lee TH, Mori W. Isolation of melatonin, the pineal factor that lightens melanocytes. J Am Chem Soc. 1958; 80:2587-2594.
• Raikhlin NT, Kvetnoy IM. Lightening effect of the extract of human appendix mucosa on frog skin melanophores. Bull Exp Biol Med. 1974; 8:114-116.
• Bubenik GA, Brown GM. Pinealectomy reduces melatonin levels in serum but not in the gastrointestinal tract of the rat. Biol Signals. 1997; 6:40-44.
• Bubenik GA, Pang SF, Hacker RR, Smith PS. Melatonin concentration in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J Pineal Res. 1996; 21:251-256.
• Huether G. Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin. Ann N Y Acad Sci. 1994; 719:146-158.
• Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia. 1993; 49:665-670.
• Bubenik GA. Localization of melatonin in the digestive tract of the rat: effect of maturation, diurnal variation, melatonin treatment and pinealectomy. Horm Res. 1980; 12:313-332.
• Messner M, Heuther G, Lorf T, Ramadori G, Schwörer H. Presence of melatonin in the human hepatobiliary-gastrintestinal tract. Life Sci. 2001; 69:543-551.
• Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, Tan DX. Nuclear loalization of melatonin in the different mammalian tissues: Immunocytochemical and radioimmunoassay evidence. J Cell Biol. 1993; 53:373 382.
• Bubenik GA, Hacker RR, Brown GM, Bartos L. Melatonin concentrations in the luminal fluid, mucosa and muscularis of the bovine and porcine gastrointestinal tract. J Pineal Res. 1999; 29:56-63.
• Tan D-X, Manchester LC, Reiter RJ, Qi W, Hanes M, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999; 65:2523 2529.
• Motilva V, Cabeza J and Alarcόn de la Lastra. New issues about melatonin and its effects on the digestive system. Current Pharmaceutical Design. 2001; 7:909-931.
• Lee PP, Pang SF. Melatonin and its receptors in the gastrointestinal tract. Biol Signals. 1993; 2:181-193.
• Bubenik GA, Dhanvantari S. Influence of serotonin and melatonin on some parameters of gastrointestinal activity. J Pineal Res. 1989; 7:333-334.
• Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept. 2001; 10:350-366.
• Poirel V-J, Cailotto C, Streicher D. MT1 melatonin receptor mRNA tisullar localization by PCR amplification. Neuroendocrinol Lett. 2003; 24:33-38.
• Arendt J. Melatonin. Characteristic, concerns and prospects. J Biol Rhythms. 2005; 20:291-303.
• Nosjean O, Ferro M, Coge F, Beaverger P, Henlin JM, Fauchere JL i wsp. Identification of the melatonin-binding site MT3 as the quinone reductase2. J Biol Chem. 2000; 275:31311-31317.
• Acuna-Castroviejevo D, ReiterRJ, Mendez-Pealez A, Burgos A. Characteri-zation of high-affinity melatonin sites in purified cell nuclei of rat liver. J Pineal Res. 1994; 16:100-112.
• Winczyk K, Lepa N. Receptory melatoninowe – obecny stan wiedzy. Endokrynol Pol. 2002; 53:365-377.
• Andre E, Gawlas K, Steinmayr M, Becker-Andre M. A novel isophorm of the orphan nuclear receptor RORβ is specially expressed in pineal gland and retina. Gene.1998; 216:277-283.
• Brzezinski A. Melatonin i humans. N Engl J Med. 1997; 336:186-192.
• Kotłowska K. Stężenia melatoniny w procesie stażenia się organizmu. Gerontol Pol. 2004; 12:111-114.
• Bubenik GA. The effect of serotonin, N- acetylserotonin, and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res. 1986; 3:45-54.
• Kato K, Murai I, Asai S, Komuro S, Matsuno Y, Matsukawa Y i wsp. Central nervous system action of melatonin on gastric acid and pepsin secretion in pylorus-ligated rats. Neuroreport. 1998; 9:3989-3992.
• Jaworek J, Nawrot K, Konturek SJ. Melatonin et its precursor L-tryptofan: influence on pancreatic enzyme secretion in vivo et in vitro. J Pineal Res. 2004; 36:156-164.
• Sjöblom M, Flemström G. Central nervous α1-adrenoeceptor stimulation induces duodenal luminal release of melatonin. J Pineal Res. 2004; 23:232-240.
• Sjöblom M, Flemström G. Melatonin in duodenal lumen is a potent stimulant of mucosal bicarbonate secretion. J Pineal Res. 2003; 34:288-293.
• Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood. 2006; 108:518-524.
• Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y. Effects of melatonin on expression of iNOS and COX2 in rat models of colitis. World J Gastroenterol. 2003; 9:1307-1311.
• Cabeza J, Alarcón-de-la-Lastra C, Jiménez D, Martín MJ, Motilva V. Melatonin modulates the effects of gastric injury in rats: role of prostaglandins and nitric oxide. Neurosignals. 2003; 12:71-77.
• Brzozowska I, Konturek PC, Brzozowski T. Role of prostaglandins , nitric oxide, sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor L-tryptofan. J Pineal Res. 2002; 32:149-162.
• Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res. 2006; 41:267-276.
• Mei Q, Yu JP, Xu JM, Wei W, Xiang L, Yue L. Melatonin reduces colon immunological injury in rats by regulating activity by macrophages. Acta Pharmacol Sin. 2002; 23:882-886.
• Reiter RJ, Tan DX, Mayo JC, Sainz RM, Camouchi L. Melatonin as antioxidant: biochemical mechanism and pathophysiological implications in humans. Acta Biochem Polon. 2003; 50:1129-1146.
• Konturek PC, Konturek SJ, Brzozowski T, Dembiński A, Zembala M, Mytar B, Hahn EG. Gastroprotective activity of melatonin and its prekursor L-tryptofan against stress-induced and ischemia- induced lesions mediated by scavenge of oxygen radicals. Scan J Gastroenterol. 1997; 32:433-438.
• Konturek PC, Konturek SJ, Majka J, Zembala M, Hahn EG. Melatonin affords protection against lesions induced by ischemia – reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol. 1997; 322:73 77.
• Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Bielanski W, Brzozowska I i wsp. The role of melatonin and L-tryptophan in preventian of acute gastric lesions induced by stress, ethanol, ischemia, and aspirin. J Pineal Res. 1997; 23:79-89.
• Voultsios A, Kennaway DJ, Dawson D. Salivary melatonin as a cicardian phase marker: validation and comparison to plasma melatonin. J Biol Rhythms. 1997; 12:457-466.
• Cutando A, Arana C, Gomez-Moreno G, Acuña-Castroviejo D, Reiter RJ. Melatonin: potential functions in oral cavity. J Periodontal. 2007; 78:1094-1102.
• Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA. Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol. 2007; 58 (Suppl 6):23-52.
• Koturek SJ, Zayachkiwska O, HawryluK O, Brzozowski T, Sliwowski Z, Pawlik Ml. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J Physiol Pharmacol. 2007; 58:371 378.
• de Souza Pereira R. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res. 2006; 41:195-200.
• Klupińska G, Wiśniewska-Jarosińska M, Harasiuk A, Chojnacki C, Stec-Michalska K, Błasiak J i wsp. Nocturnal secretion of melatonin in patients with upper digestive tract disorder. J Physiol Pharmacol. 2006; 57 (Suppl 5):41-50.
• Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern The Health Med. 2008; 14:54-58.
• Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastroesphageal disease. BMC Gastroenterol. 2010, 18:10-17.
• Konturek PC, Konturek SJ, Hahn EG. Duodenal alkaline secretion: its mechanism and role in mucosal protection against gastric acid. Dig Liver Dis. 2004; 36:505 512.
• Konturek PC, Konturek SJ, Majka J, Zembala M, Hahn EG. Melatonin affords protection against lesions induced by ischemia – reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol. 1997; 322:73-77.
• Liaw SJ, Chen YC, NG CJ, Chin DF, Chen MF, Chen HM. Beneficial role of melatonin on microcirculation in endotoxin induced gastropathy in rats: possible implication in nitrogen oxide reduction. J Fomos Med Assae. 2002; 101: 129-135.
• Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res. 2006; 41:267-276.
• Sener-Muratoglu G, Paskaloglu K, Arbach S, Hurdag C, Ayanoglu-Dulger G. Protective effect of famotidine, omeprazole and melatonin against acetylosalicylic acid-induced gastric damage in rats. Dig Dis Sci. 2001; 46:318-330.
• Bilici D, Suleyman H, Banoglu ZN, Kiziltanc A, Avci B, Cifcioglu A i wsp. Melatonin prevents ethanol-induced gastric mucosal damage possibly due to its antioksidant effect. Dig Dis Sci. 2002; 47:856-861.
• Bandyopadhyay D, Bandyopadhyay A, Das PK, Reiter RJ. Melatonin protects against gastric ulceration and increases efficacy of ranitidine and omeprazole in reducing gastric damage. J Pineal Res. 2002; 33:1-7.
• Cabeza J, Jimenez D, martin MJ, Motilva V. Melatonin modulates the effects of gastric injury in rat: role of prostaglandins and nitric oxide. Neurosignals. 2003; 12:71-77.
• Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res. 2006; 41:267-276.
• Sener G, Goren FO, Ulusoy NB, Ersoy Y, Arbak S, Dülger GA. Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Dig Dis Sci. 2005; 50:1506–1512.
• Komarov FI, Rappoport SI, Malinovskaia NK, Voznesenskaia LA, Vetterberg L. Melatonin: ulcer disease and seasons of the year. Klin Med. 2003; 81:17-21.
• Rapoport SI, Raikhlin NT, Malinovskaia NK, Lakshin AA. Ultrastructural changes in cells of the antral gastric mucosa in patients with duodenal ulcers treated with melatonin. Ter Arch. 2003; 75:10-14.
• Harasiuk A, Klupińska G, Walecka-Kapica E, Foryś S, Felicka E, Piotrowski W i wsp. Secretion of serotonin and melatonin in patients with functional dyspepsia. Pol Merkur Lek. 2007; 22:336-340.
• Kulig G, Klupińska G, Jochymski C, Wiśniewska-Jarosińska M, Kozłowski W, Chojnacki J. Evaluation of the number of enterochromaffin cells in gastric mucosa in subjects with functional dyspepsia. Pol Merkur Lek. 2009; 26:370-372.
• Klupińska G, Popławski T, Drzewoski J, Harasiuk A, Reiter RJ, Błasiak J i wsp. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol. 2007; 41:270-274.
• Barajas-Lopez C, Peres AL, Espinosa-Luna R, Reyes-Vazquez C, Prieto-Gomez B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucosus plexus. Eur J Pharmacol. 1996; 312:319-325.
• Benouali-Pellissier S. Melatonin is involved in cholecystokinin–induced changes of ileal motility in rats. J Pineal Res. 1994; 17:79-85.
• Mach T. The brain – gut axis in irritable bowel syndrome. Med Sci Monit. 2004; 10:125-131.
• Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M i wsp. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and post dysenteric irritabile bowel syndrome. Gut. 2000; 47:804-811.
• El-Sahly M, Norrgard O, Spinnell S. Abnormal colonic endocrine celle in patients with chronic idiopatic slow-transit constipation. Scand J Gastroendocrinol. 1999; 34:1007-1011.
• Stępień A, Moskwa-Fortuna A, Wiśniewska-Jarosińska M, Harasiuk A, Chojnacki J. Melatonin secretion na metabolism in patients with irritable bowel syndrome. Pol Merkur Lek. 2009; 26:440-443.
• Radwan P, Skrzydło-Radomańska B, Radwan-Kwiatek K, Burak-Czapiuk B, Strzemecka J. Is melatonin involved in the irritable bowel syndrome? J Physiol Pharmacol. 2009; 60 (Suppl 3):67-70.
• Saha L., Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bpwel syndrome. J Clin Gastroenterol. 2007; 41:29-32.
• Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, doble blind, placebop controlled study. Gut. 2005; 54:1353-1354.
• Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2005; 22:927-934.
• Mendlewicz J, Branchery L, Weiberg U, Branchery M, Linkowski P, Weitzman ED. The 24-hour pattern of plasma melatonin in the depressed patients before and after treatment. Commun Psychopharmacol. 1980; 4:49-55.
• Rosenthal NE. Melatonin in seasonal affective disorder and phototherapy. J Neurol Transm. 1986; suppl 21:257-267.
• Stewart JW, Quinthin FM, Therman MT, Therman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry Res. 1990; 33:121-128.
• Pentney PT, Bubenik GA: Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res. 1995; 19:31-39.
• Cuzzocrea S, Mazzon E, Serraino I, Lepore V, Terranova ML, Ciccolo A i wsp. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res. 2001; 30:1-12.
• Marquez E, Sánchez-Fidalgo S, Calvo JR, la de Lastra CA, Motilva V: Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res. 2006; 40:48-55.
• Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol. 2003; 9:1307-1311.
• Necefli A, Tulumoğlu B, Giriş M, Barbaros U, Gündüz M, Olgaç V i wsp. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci. 2006; 51:1538-1545.
• Mei Q, Yu JP, Xu JM, Wei W, Xiang L, Yue L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin. 2002; 23:882-886.
• Mazzon E, Esposito E, Crisafulli C, Riccardi L, Muià C, Di Bella P i wsp. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res. 2006; 41:363-373.
• Boznańska P, Wichan P, Stępień A, Wiśniewska-Jarosińska M, Śmigielski J, Szadkowski K. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lek. 2007; 22:369-372.
• Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms and future research. Inflamm Bowel Dis. 2009; 15:134-140.
• Kvetnoy IM, Levin OM: Diurnal melatonin excretion in gastric and rectal cancer. Voprosi onkologii. 1987; 33:29-32.
• Khoory R, Stemme D: Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res. 1988; 5:251-258.
• Kos-Kudla B, Ostrowska Z, Kozlowski A, Marek B, Ciesielska-Kopacz N, Kudla M i wsp. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuroendocrinol Lett.2002; 23:239-242.
• Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klakla K. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. J Exp Clin Cancer Res. 2003; 22:171-178.
• Vician M, Zeman M, Herichova I, Blazieek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res. 1999; 27:164-169.

• Document Type: paper